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Background
Doxorubicin is an antibiotic largely used in clinical prac-
tice for the treatment of several types of tumors. However,
its application may be limited by triggering some host’s
deleterious effects, such as extreme fatigue, anorexia, sar-
copenia, cardiovascular diseases, among others [1]. The
role of skeletal muscle in this process should be further
elucidated as this tissue is still important for glucose
homeostasis [2] and becomes impaired by doxorubicin
treatment. Knowledge of doxorubicin’s effect in the skele-
tal muscle and in the mechanism of action involved on the
systemic insulin sensitivity is still incipient. The aim of this
study is to evaluate the mechanism of insulin resistance
after doxorubicin treatment.
Materials and methods
Wistar rats received a single dose of intraperitoneal
injection of doxorubicin (DOX) or saline (CT) at a dose
of 15 mg/kg body. After 48h, some of the animals were
submitted to evaluation of systemic insulin sensitivity by
insulin tolerance test (iTT). After 72h the following
parameters were analyzed: basal glycemia and insuline-
mia, mRNA expression of insulin pathway in EDL mus-
cle (AKT, GLUT4, IRS-1, GSK3-b and AMPk) and
activity of mitochondrial complexes, in EDL muscle.
The groups were compared by Test T. p < 0.05 was
considered statistically significant.
Results
After 72 hours, the Dox group showed a decrease in
body weight and food intake. Insulin sensitivity assessed
by ITT was decreased in the DOX group, corroborating
the data of systemic resistance assessed by elevated
basal insulin and glucose. There was an increase in the
mitochondrial complex 1 activity and a decrease in com-
plex 3 activity. mRNA expression of the insulin signaling
pathway in skeletal muscle was altered by treatment.
The DOX group showed a decrease of IRS-1, GLUT4,
AMPK and GSK3b expression. Gene expression of AKT
was not altered.
Conclusions
Our data suggests that doxorubicin causes systemic insulin
resistance and also alters the expression of genes involved
in insulin signaling in skeletal muscle. AMPK may be
responsible for one of the paths of insulin resistance devel-
opment in the DOX group.
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